PT - JOURNAL ARTICLE AU - Watanabe, Marika AU - Yakushijin, Kimikazu AU - Funakoshi, Yohei AU - Ohji, Goh AU - Ichikawa, Hiroya AU - Sakai, Hironori AU - Hojo, Wataru AU - Saeki, Miki AU - Hirakawa, Yuri AU - Matsumoto, Sakuya AU - Sakai, Rina AU - Nagao, Shigeki AU - Kitao, Akihito AU - Miyata, Yoshiharu AU - Koyama, Taiji AU - Saito, Yasuyuki AU - Kawamoto, Shinichiro AU - Yamamoto, Katsuya AU - Ito, Mitsuhiro AU - Murayama, Tohru AU - Matsuoka, Hiroshi AU - Minami, Hironobu TI - A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients AID - 10.1101/2022.10.08.22280863 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.08.22280863 4099 - http://medrxiv.org/content/early/2022/10/11/2022.10.08.22280863.short 4100 - http://medrxiv.org/content/early/2022/10/11/2022.10.08.22280863.full AB - We previously reported that a second dose of COVID-19 mRNA vaccine was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. However, some of these patients did not achieve seroconversion. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in Japanese allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of COVID-19 mRNA vaccine. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Median time from HSCT to the third vaccination and from the second to the third vaccination was 1842 (range, 378–4279) days and 219 (range, 194–258) days, respectively. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Median optical density of S1 IgG titers before and after the third dose was 0.099 (range, 0.001–0.713) and 1.315 (range, 0.006–1.730), respectively. Among 22 evaluable patients, 21 (95%) seroconverted after the third dose. Four of the five patients treated with steroids or CI seroconverted after the third vaccination. One patient with a serum IgG level of 173 mg/dL who received steroids did not achieve seroconversion. On one-week follow-up, none of our patients had > grade 3 or serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. The most frequent adverse event was mild pain at the injection site. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.Competing Interest StatementHironobu Minami has received research grants and honoraria from Pfizer. Kimikazu Yakushijin has received honoraria from Pfizer. Hironori Sakai and Wataru Hojo are employed by Cellspect. The other authors declare no potential conflicts of interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Kobe University Hospital Ethics Committee gave ethical approval for this work(No. B2056714, 1481).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.